Evotec AG provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates in two segments, EVT Execute and EVT Innovate. The EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody platform; INDiGO, a program for accelerating the early drug candidates into the clinic stage; integrated chemistry, manufacturing, and control services; and integrated drug discovery services.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone49-4056-0810
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$443.55 million
Profitability
Miscellaneous
Employees2,617
Next Earnings Date3/17/2020 (Estimated)
OptionableNot Optionable
Evotec (OTCMKTS:EVTCY) Frequently Asked Questions
What is Evotec's stock symbol?
Evotec trades on the OTCMKTS under the ticker symbol "EVTCY."
When is Evotec's next earnings date?
What is the consensus analysts' recommendation for Evotec?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evotec in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Evotec.
Has Evotec been receiving favorable news coverage?
Press coverage about EVTCY stock has trended neutral recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Evotec earned a news sentiment score of 0.2 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Evotec.
Who are some of Evotec's key competitors?
Some companies that are related to Evotec include Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Bausch Health Companies (BHC), Teva Pharmaceutical Industries (TEVA), Elanco Animal Health (ELAN), Mylan (MYL), Ono Pharmaceutical (OPHLF), Ionis Pharmaceuticals (IONS), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ), Amarin (AMRN), Catalent (CTLT), Sarepta Therapeutics (SRPT) and Perrigo (PRGO).
What other stocks do shareholders of Evotec own?
Who are Evotec's key executives?
Evotec's management team includes the folowing people:
- Dr. Werner Lanthaler, CEO & Member of Management Board (Age 51)
- Mr. Enno Spillner, CFO & Member of Management Board (Age 49)
- Dr. Cord Dohrmann, Chief Scientific Officer & Member of Management Board (Age 55)
- Dr. Craig Johnstone, COO & Member of Management Board
- Ms. Anja Bosler, Principal Accounting Officer and Sr. VP of Group Accounting
How do I buy shares of Evotec?
Shares of EVTCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Evotec's stock price today?
One share of EVTCY stock can currently be purchased for approximately $47.79.
How big of a company is Evotec?
Evotec has a market capitalization of $3.56 billion and generates $443.55 million in revenue each year. The company earns $99.41 million in net income (profit) each year or $1.32 on an earnings per share basis. Evotec employs 2,617 workers across the globe.View Additional Information About Evotec.
What is Evotec's official website?
How can I contact Evotec?
Evotec's mailing address is Manfred Eigen Campus Essener Bogen 7, Hamburg 2M, 22419. The company can be reached via phone at 49-4056-0810 or via email at [email protected]
MarketBeat Community Rating for Evotec (OTCMKTS EVTCY)
MarketBeat's community ratings are surveys of what our community members think about Evotec and other stocks. Vote "Outperform" if you believe EVTCY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVTCY will underperform the S&P 500 over the long term. You may vote once every thirty days.
